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The overall burden of heart failure (HF) continues to increase because of aging population and increasing 
cardiovascular (CV) risk factors in low- and middle-income 
countries.1,2 The prognosis of patients with established HF 
remains poor despite many partially effective treatments. To 
reduce death and disability, both early identification of popu-
lations at risk and prevention of HF are increasingly empha-
sized strategies in professional guidelines.3 However, such 
strategies remain poorly developed and implemented.4
Clinical Perspective on p 210
Diabetes mellitus is an important risk factor for HF, and 
the level of glycated hemoglobin (HbA1c) is associated with 
the magnitude of risk of incident HF and worse outcomes.5,6 
In addition, among patients without diabetes mellitus, 
high-to-normal HbA1c (≥5.5%–6%) is associated with 
increased rates of incident HF.7 Other studies in selected 
populations have shown that impaired glucose tolerance 
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Background—Impaired glucose tolerance and metabolic syndrome are associated with increased risk of heart failure (HF). 
However, predictors associated with the increased risk of incident HF have not been well characterized. We aimed to 
identify independent predictors of incident HF hospitalization among patients with impaired glucose tolerance.
Methods and Results—In Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR), 
9306 research participants with impaired glucose tolerance and ≥1 cardiovascular risk factors were randomized to 
valsartan versus placebo and nateglinide versus placebo in a 2×2 factorial manner, with a median follow-up of 6.5 years. 
Using a multivariable Cox proportional hazards model, we analyzed the relationships among baseline clinical factors 
and the outcome of incident HF hospitalization in patients without history of HF. Significant predictors were identified 
by forward selection. Increasing age, history of coronary heart disease, and atrial fibrillation or flutter were among 
several known independent predictors of incident HF hospitalization. Increased waist circumference (hazard ratio per 10 
cm, 1.37; 95% confidence interval, 1.21–1.55; P<0.001) and increased urinary albumin–creatinine ratio (P<0.001) were 
identified as novel predictors. The predictive model for incident HF hospitalization showed good discrimination, with an 
optimism-corrected C-index of 0.79.
Conclusions—Among research participants with impaired glucose tolerance, there are several easily identifiable predictors 
of incident HF hospitalization, including traditional risk factors and novel indices of central adiposity and increased 
urinary albumin–creatinine ratio, which enable further risk stratification and help distinguish patients who could benefit 
from more aggressive risk factor management. (Circ Heart Fail. 2013;6:203-210.)
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(IGT) is independently associated with the risk of incident 
HF.8 In addition to the well-established risk associated 
with comorbidities, such as coronary heart disease and 
hypertension, that are prevalent in this patient population, 
several other potential pathophysiological mechanisms 
underlie the association between IGT and HF. Insulin 
resistance in patients with IGT may contribute to impaired 
myocardial energy metabolism and increased free fatty 
acid utilization.9,10 Accumulation of advanced glycation end 
products in the presence of dysglycemia and hyperinsulinemia 
may also lead to increased myocardial fibrosis and adverse 
ventricular remodeling.11
Because patients with IGT are at risk of developing dia-
betes mellitus and HF, this patient population may benefit 
from early identification and preventative measures. By iden-
tifying patients while they are in earlier disease stages, who 
are either at risk of developing clinical HF (American Heart 
Association/American College of Cardiology Stage A) or who 
have asymptomatic left ventricular dysfunction (American 
Heart Association/American College of Cardiology Stage B), 
potential treatment strategies can be developed. However, fur-
ther risk stratification can refine the selection of patients to 
minimize unnecessary screening and to enable a more targeted 
prevention strategy. To address these issues, this analysis 
aimed to characterize the risk of incident HF hospitalization 
and associated predictors among patients with diagnosed IGT 
and CV disease or CV risk factors who were enrolled in the 
Nateglinide and Valsartan in Impaired Glucose Tolerance 
Outcomes Research (NAVIGATOR) trial.
Methods
Study Population
The design and results of NAVIGATOR have been previously pub-
lished.12 In brief, NAVIGATOR was a prospective, double-blinded, 
randomized, 2×2 factorial clinical trial that enrolled 9306 research par-
ticipants aged 50 years or older with IGT and prior CV diseases or risk 
factors. A complete version of the study protocol was published as on-
line-only Data Supplement material with earlier articles.12 IGT was de-
fined as 2-hour postchallenge glucose after a 75 g oral glucose tolerance 
test ≥140 mg/dL (7.8 mmol/L) but <200 mg/dL (11.1 mmol/L) at base-
line and a fasting plasma glucose concentration of at least 95 mg/dL (5.3 
mmol/L) but <126 mg/dL (7.0 mmol/L). Patients with a history of New 
York Heart Association class III–IV symptomatic HF were excluded 
from enrollment. Although patients with New York Heart Association 
class I–II HF were included in NAVIGATOR, these patients were ex-
cluded from this analysis. Patients were randomized to valsartan or pla-
cebo and, in addition, nateglinide or placebo. All research participants 
were required to follow a standardized lifestyle modification program. 
The primary outcomes of the main study were as follows: (1) develop-
ment of diabetes mellitus; (2) a core CV composite of CV death, non-
fatal myocardial infarction, nonfatal stroke, or HF hospitalization; and 
(3) an extended CV composite that included hospitalization for unstable 
angina and arterial revascularization in addition to the core composite 
outcome components. Analysis of the individual components of the 
core CV outcome was also prespecified. Randomized patients were fol-
lowed for a median of 5 years for the incident diabetes mellitus end 
point and 6.5 years for vital status. All research participants enrolled in 
NAVIGATOR were included in this analysis.
Definition of HF
Incident HF hospitalization was defined as development of >1 symp-
tom and >1 sign of HF not present at screening and requiring hos-
pital management. The NAVIGATOR study end point committee 
independently adjudicated these events in a blinded fashion based 
on predefined event definitions that included subjective symptoms 
of HF and objective physical signs, imaging findings, or elevated 
brain natriuretic peptide level (Appendix I in the online-only Data 
Supplement). Only events that required overnight hospital admission 
were included as end point events for this analysis.
Definitions of Baseline Variables
Coronary heart disease included prior myocardial infarction, revascu-
larization procedure, or symptomatic angina. Similarly, cerebrovas-
cular disease consisted of prior stroke or transient ischemic attack. 
Peripheral artery disease included nontraumatic limb or foot amputa-
tion, peripheral revascularization procedure, or significant peripheral 
arterial stenosis (>50%) on angiography. Chronic obstructive pulmo-
nary disease (COPD) included chronic bronchitis, emphysema, or 
COPD. Current cigarette smoking status was defined by self-reported 
history of smoking. Patients who had quit smoking <12 months be-
fore enrollment were considered as current smokers. Baseline ECGs 
were reported by investigators using a predefined classification with 
the following checkbox options on the case report form: (1) normal, 
(2) clinically insignificant abnormality, and (3) clinically significant 
abnormality.
Statistical Analysis
Continuous baseline variables were summarized as means±SDs, 
except where otherwise noted. Between groups, comparisons were 
performed using t tests for normally distributed data or nonparamet-
ric tests (Wilcoxon rank-sum) otherwise. Categorical variables were 
summarized as counts and percentages and were compared using χ2 
tests or the Fisher exact test.
Predictive Model Development
A multivariable Cox proportional hazards model was developed for 
the outcome of incident HF hospitalization. For model selection, can-
didate variables included demographic features, baseline comorbidi-
ties, vital signs, anthropometric measurements, laboratory values, and 
investigator-reported baseline ECG results (Table 1). The number of 
candidate variables was limited to 25 to reduce the likelihood of over-
fitting, given the number of events relative to the number of candidate 
predictors being considered. These variables were statistically signifi-
cant predictors identified by the Cox model and developed for all HF 
hospitalizations (including patients with history of congestive HF), 
which had a more extensive set of candidate variables (Appendix II 
in the online-only Data Supplement). This was not intended as a vari-
able screening process, but given the importance of these variables in 
the overall population, there was strong rationale to include them in 
the incident HF hospitalization analysis. In addition, several other key 
variables (sex, race, baseline history of hypertension, cerebrovascular 
disease, renal dysfunction, current smoking at baseline, family his-
tory of diabetes mellitus, fasting glucose, oral glucose tolerance test 
result, heart rate, and low-density lipoprotein) were specifically iden-
tified by the authors based on clinical relevance and were included 
in the model selection process. Of note, waist circumference was the 
only obesity measure included as a candidate variable. Weight and 
body mass index (BMI) were not included, as they were not found 
to be significant independent predictors in the presence of waist cir-
cumference in the all HF hospitalization model (Appendix III in the 
online-only Data Supplement). Similarly, baseline HbA1c was not 
included as a candidate variable, as it was not found to be a signifi-
cant predictor in the all HF hospitalization model. In addition, not 
all research participants were required to have a baseline HbA1c as 
part of inclusion. However, because of the clinical importance of both 
BMI and HbA1c, these variables were tested in the final incident HF 
hospitalization model to confirm nonsignificance. Restricted cubic 
splines were used to assess linearity of continuous variables. For vari-
ables that were found to be nonlinear, appropriate transformations, 
such as logarithmic transformation (urinary albumin–creatinine ratio 
[UACR]) or linear splines (systolic blood pressure [BP]), were ap-
plied. Variable selection for the final model was based on forward se-
lection (variables were sequentially added to the developing model), 
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Table 1. Baseline Characteristics of Research Participants With or Without Incident Heart Failure Hospitalization
Baseline Characteristics No HF Hospitalization (N=8851) Incident HF Hospitalization (N=124) P Value
Demographics
 Age, y* 63.6±6.8 68.7±7.8 <0.001
 Female* 4523 (51.1) 56 (45.2) 0.189
 Race*
  White 7331 (82.8) 106 (85.5) …
  Black 223 (2.5) 4 (3.2) …
  Asian 595 (6.7) 5 (4.0) …
  Other 702 (7.9) 9 (7.3) …
Anthropometric variables
 Weight, kg 83.4±17.1 86.1±17.5 0.056
 Height, cm* 165.3±9.9 164.9±9.5 0.612
 BMI, kg/m2 30.4±5.4 31.7±6.1 0.022
 Waist circumference, cm* 100.8±13.5 105.6±14.2 <0.001
  Male 103.6±12.4 107.3±13.2 0.002
  Female 98.1±13.9 103.6±15.1 0.015
Clinical features
 Systolic blood pressure, mm Hg* 139.7±17.3 141.0±22.2 0.674
 Diastolic blood pressure, mm Hg 82.6±10.1 80.9±13.6 0.027
 Heart rate, bpm 70.2±10.6 68.4±11.1 0.092
Medical history
 Hypertension* 6840 (77.3) 101 (81.5) 0.270
 Left ventricular hypertrophy 230 (2.6) 4 (3.2) <0.567
 Coronary heart disease* 2304 (26.0) 66 (53.2) <0.001
 Current smoker* 974 (11.0) 10 (8.1) 0.298
 Atrial fibrillation or flutter* 261(2.9) 19 (15.3) <0.001
 Cerebrovascular disease* 665 (7.5) 15 (12.1) 0.055
 Peripheral artery disease* 277 (3.1) 11 (8.9) 0.002
 Renal dysfunction* 67 (0.8) 3 (2.4) 0.072
 COPD/chronic bronchitis/emphysema* 374 (4.2) 17 (13.7) <0.001
 Pulmonary embolism and DVT 118 (1.3) 5 (4.0) 0.028
 Family history of premature CHD 1467 (16.6) 19 (15.3) 0.710
 Family history of diabetes mellitus* 3401 (38.4) 35 (28.2) 0.020
Glycemic status
 Plasma glucose level, mmol/L
  Baseline fasting* 6.1±0.5 6.1±0.4 0.506
  2 h after glucose challenge* 9.2±0.9 9.1±1.0 0.718
  Glycated hemoglobin, % 5.8±0.4 5.9±0.5 0.004
Baseline ECG interpretation* <0.001
 Normal 4439 (50.2) 31 (25.0) …
 Clinically insignificant abnormality 3147 (35.6) 48 (38.7) …
 Clinically significant abnormality 1265 (14.3) 45 (36.3) …
Baseline laboratory results
 Sodium, mmol/L 142.4±2.5 142.4±2.7 0.944
 Potassium, mmol/L 4.3±0.4 4.4±0.5 0.145
 Hemoglobin, g/L* 146.8±12.6 143.9±13.4 0.030
 Platelets, ×109/L* 257.8±63.7 243.4±66.3 0.016
 White blood cells, ×109/L* 6.9±1.7 7.1±1.7 0.104
 eGFR, mL/min per 1.73m2* 80.9±18.0 73.1±18.3 <0.001
(Continued)
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with the α level set at 0.05. Multilevel categorical variables such as 
race (eg, black, white, Asian, and other) and ECG findings were test-
ed as a group.
The discrimination ability of the models was assessed with 
C-statistics, which were corrected for optimism induced by assess-
ing the model in the derivation dataset. The optimism correction was 
achieved by bootstrapping the incident HF hospitalization dataset 
and repeating the model selection from among 25 covariates, in 100 
bootstrap samples.13 A plot of observed and predicted event rates was 
developed to visualize the calibration of the predictive model.
Results
Among the 9306 research participants enrolled in the NAV-
IGATOR study, 331 patients with history of HF at baseline 
were excluded, resulting in a cohort of 8975 research partici-
pants for this analysis. During the median follow-up of 6.5 
years (interquartile range, 6.0–6.9), 124 patients experienced 
an incident HF hospitalization (event rate of 2.3 per 1000 
patient-years).
Patient Characteristics
The baseline characteristics of patients with and without 
incident HF hospitalization differed significantly (Table 1). 
Patients with HF hospitalization were older, had a larger waist 
circumference (for both males and females), and were more 
likely to have coronary heart disease, atrial fibrillation or 
flutter, peripheral artery disease, or COPD. The majority of 
patients, with or without incident HF hospitalization, had a 
history of hypertension (81.5% and 77.3%, respectively). At 
baseline, patients with subsequent incident HF hospitaliza-
tion were also more likely to have a clinically significant ECG 
abnormality reported by investigators. The baseline estimated 
glomerular filtration rate was lower among patients with inci-
dent HF hospitalization than among those without; however, 
the majority of research participants had preserved renal func-
tion. At randomization, patients with subsequent incident HF 
hospitalization were more likely to have been prescribed an 
antihypertensive agent, angiotensin-converting enzyme inhib-
itor, β-blocker, or diuretic.
Predictors of Incident HF Hospitalization
The strongest predictors of incident HF hospitalization were 
older age and central adiposity indicated by an increase in 
waist circumference (Table 2). Every 10 cm increase in waist 
circumference was associated with a 37% increased risk of HF 
hospitalization. In addition, taller height was associated with 
better prognosis.
Baseline history of coronary heart disease, atrial fibril-
lation or flutter, and COPD were associated with increased 
risk of incident HF hospitalization. A clinically significant 
abnormal ECG (compared with a normal ECG at baseline) 
was associated with a 1.8× increased risk of incident HF 
hospitalization. In the presence of COPD, cigarette smoking 
was not found to be an independent predictor of incident HF 
hospitalization.
Systolic BP was found to be a nonlinear continuous vari-
able when the restricted cubic spline was examined. Based 
on the spline, systolic BP was truncated at 130 mm Hg and a 
marginal protective effect was associated with every 1 mm Hg 
increase in systolic BP up to 130 mm Hg. Systolic BP lev-
els above 130 mm Hg were not significantly associated with 
HF hospitalization in this multivariable regression model. In 
the presence of systolic BP as a continuous variable, baseline 
Table 1. Continued
Baseline Characteristics No HF Hospitalization (N=8851) Incident HF Hospitalization (N=124) P Value
 UACR, mg/mmol† 0.8 (0.5–1.7) 1.3 (0.6–4.5) <0.001
 Log UACR* 0.1±1.1 0.7±1.4 <0.001
 HDL cholesterol, mmol/L 1.3±0.3 1.3±0.3 0.240
 LDL cholesterol, mmol/L* 3.3±0.9 3.2±1.0 0.185
 Triglycerides, mmol/L 1.9±1.1 1.9±1.1 0.209
Medications at randomization‡
 Any antihypertensive 6393 (72.2) 109 (87.9) <0.001
  ACE inhibitors 501 (5.7) 21 (16.9) <0.001
  Angiotensin receptor blocker 30 (0.3) 0 (0) 1.000
  α-Blocker 545 (6.2) 13 (10.5) 0.048
  β-Blocker 3392 (38.3) 66 (53.2) 0.001
  Calcium channel blocker 2870 (32.4) 54 (43.5) 0.009
 Diuretics 2697 (30.5) 51 (41.1) 0.011
 Lipid-lowering drug 3394 (38.3) 54 (43.5) 0.237
 Aspirin 3183 (36.0) 56 (45.2) 0.034
Continuous variables are presented as means±SDs. Categorical variables are presented as actual frequencies (n) and percentages (%). 
ACE indicates angiotensin-converting enzyme; BMI, body mass index; bpm, beats per minute; CHD, coronary heart disease; COPD, chronic obstructive pulmonary 
disease; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HF, heart failure; IQR, interquartile range; LDL, low-density 
lipoprotein; and UACR, urinary albumin–creatinine ratio.
*Variables included as candidate variables for the incident heart failure hospitalization predictive model.
†Urinary albumin–creatinine ratio summarized as median with IQR.
‡Medications at randomization were not included in the multivariable models as candidate variables.
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history of hypertension was not independently associated with 
increased risk of incident HF hospitalization.
Albuminuria, expressed as log of UACR, was also found to 
be an independent predictor of HF hospitalization. Of note, 
the median UACR is well below the range for microalbumin-
uria (>3.5 mg/mmol). Baseline estimated glomerular filtration 
rate or history of renal dysfunction was not independently 
associated with incident HF hospitalization.
When added to the final model (Table 2) sequentially, nei-
ther BMI nor HbA1c were shown to be significant (P=0.373 
and P=0.398, respectively).
Model Performance
The Cox regression model showed good discriminatory abil-
ity, with an optimism-corrected C-index of 0.79. In addition, 
the predicted probability of incident HF hospitalization was 
very similar to the observed probabilities. The Figure shows 
the calibration plot for the incident HF hospitalization Cox 
model with probability risks divided into quintiles.
Discussion
In this well-characterized cohort of patients with IGT, the 
overall event rate of incident HF hospitalization during the 
trial follow-up period was 2.3 per 1000 patient-years. In 
addition to previously well-recognized determinants for the 
development of HF, this study also identified several novel 
predictive factors, such as increased waist circumference, 
taller body height, and increased UACR.
Obesity is an emerging risk factor for HF. Several epide-
miological studies have established an incremental relation 
between obesity, as measured by BMI, and the incidence 
of HF across several communities.14–16 In addition, other 
anthropometric measures of central obesity, such as waist 
circumference, have been shown to be independently 
associated with the risk of HF in several studies.17–20 The 
Atherosclerosis Risk in Communities study showed that 
BMI, waist circumference, and waist-to-hip ratio were all 
independently associated with increased risk of incident HF 
hospitalization or death.20 However, most studies, with the 
Table 2. Multivariable Cox Proportional Hazards Model Showing Independent Baseline Predictors of Incident Heart Failure 
Hospitalizations Among Patients With Impaired Glucose Tolerance
Baseline Characteristics HR (95% CI) χ2 Statistics P Value
Age (per 10 y increase) 2.27 (1.77–2.93) 41.24 <0.001
Waist circumference (per 10 cm increase) 1.37 (1.21–1.55) 24.72 <0.001
History of coronary heart disease 2.42 (1.67–3.51) 21.97 <0.001
Baseline clinically significant abnormal ECG (vs normal) 2.81 (1.73–4.55) 17.58 <0.001
History of atrial fibrillation or flutter 2.64 (1.56–4.47) 13.14 <0.001
Log of urinary albumin–creatinine ratio 1.25 (1.10–1.41) 12.51 <0.001
History of COPD/emphysema/chronic bronchitis 2.46 (1.46–4.13) 11.50 <0.001
Systolic BP up to 130 mm Hg* (per unit increase) 0.97 (0.94–0.99) 7.21 0.007
Hemoglobin (per 10 g/L decrease) 1.17 (1.01–1.35) 4.41 0.036
Height (per 10 cm increase) 0.82 (0.67–0.99) 4.17 0.041
Baseline clinically insignificant abnormal ECG (vs normal) 1.58 (1.00–2.50) 3.79 0.051
Optimism-corrected C-statistic for this model was 0.79. 
BP indicates blood pressure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; and HR, hazard ratio.
*Selected due to nonlinearity of systolic blood pressure as a continuous variable.
Figure.  Calibration plot showing observed vs 
predicted probability of incident heart failure hos-
pitalization at 5-year follow-up. The predicted 
probability estimates represent mean predicted 
probability from the Cox proportional hazards 
regression model, and observed probability esti-
mates of the trial population were derived from 
Kaplan–Meier estimates. Predicted probability 
was divided into quintiles to represent each risk 
category.
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exception of 1 study of elderly patients (aged 70–79),19 did 
not take into account the glycemic status of patients, which 
is an important confounder in the context of metabolic syn-
dromes and incident HF. The strength of our study is that 
increased waist circumference was shown to be a significant 
predictor of incident HF hospitalization, independent of a 
wide range of CV comorbidities, 2-hour oral glucose toler-
ance test results, and fasting glucose levels. These findings 
may support recent evidence suggesting that increased lev-
els of adipokines secreted by visceral fat, such as resistin, 
are associated with increased risk of HF.9,21,22 Nonetheless, 
further study is needed to clarify whether excess visceral 
adiposity is indeed a contributor to the development of HF 
in patients with dysglycemia. In addition, the inverse rela-
tion between body height and the risk of HF hospitalization, 
when interpreted in conjunction with waist circumference, 
further strengthens the focus of central adiposity’s impor-
tance as a predictive factor.
Albuminuria, measured by UACR, has been found to be an 
independent predictor of adverse prognosis in patients with 
chronic HF.23 Our study’s finding that albuminuria is an inde-
pendent predictor of incident HF hospitalization extends the 
observation that increased urinary albumin excretion is in 
some way connected with the pathophysiology of HF. In a 
study of 10 975 patients without HF at baseline, Blecker et 
al24 found a linear relationship between UACR and the risk 
of incident HF after adjusting for multiple established risk 
factors and possible confounders. The linear relationships 
remained significant across the range of UACRs, starting 
from a detectable but within normal range of albuminuria to 
levels consistent with macroalbuminuria. This UACR–HF 
relationship was independent of the estimated glomerular fil-
tration rate. Our observation in a cohort with IGT is consis-
tent with previous population-based studies. Several possible 
mechanisms explaining the association have been postulated: 
albuminuria is most likely a marker of (1) activation of the 
renin-angiotensin aldosterone system,25 (2) impaired vascular 
endothelial function with consequent increased renal vascu-
lature permeability,26 and (3) association with left ventricular 
hypertrophy.27
A history of hypertension at baseline and systolic BP above 
130 mm Hg were not found to be independent predictors of 
incident HF hospitalization in our study. Several factors con-
tributed to this observation. First, hypertension was highly 
prevalent in the overall study population: the prevalence of 
hypertension at baseline was >75% in those with and with-
out subsequent HF hospitalization. This makes hypertension 
at baseline a poor discriminator for the selected end point. 
Second, continuous effort was made in NAVIGATOR to 
adhere to evidence-based recommendations for BP control, 
with a noticeable improvement in the overall mean systolic BP 
from a baseline of 140 mm Hg to 134 mm Hg (median systolic 
BP, 133 mm Hg) after 5 years of follow-up.12 Systolic BP at 
baseline as a continuous variable was found to have a nonlin-
ear relationship with HF hospitalization. Higher systolic BP 
up to 130 mm Hg was associated with a better outcome, per-
haps due to confounding by the possibility that patients with 
subclinical left ventricular dysfunction and low BP (due to 
reduced cardiac output) are more likely to have poorer prog-
noses and higher risks of hospitalization.
Whereas not all risk factors are modifiable, earlier identifi-
cation of patients at risk for HF may allow closer surveillance 
and additional therapeutic interventions to prevent worsening 
HF requiring hospitalization. Recognizing that IGT is associ-
ated with an increased risk of HF and other CV diseases, fur-
ther screening of patients with central obesity and other risk 
factors identified in our analyses may be warranted if these 
findings are strengthened and validated in independent analy-
ses. Multiple studies have found that IGT and diabetes melli-
tus itself are often missed in practice, both in patients with and 
without extant vascular disease. The independent predictors 
identified in this analysis will help clinicians to further stratify 
a patient within this population for the risk of incident HF.
Limitations
There are several limitations to this study. First, incident 
HF hospitalization was defined by a lack of clinical history 
of existing HF at baseline, without objective screening tests, 
potentially creating a prevalence-incidence bias. Second, we 
were unable to differentiate between HF with (1) reduced 
or (2) preserved ejection fraction. Furthermore, only HF 
events requiring hospitalization were included in this analy-
sis; patients with HF treated as outpatients were not cap-
tured. Third, we evaluated associations with 25 covariates in 
a sample with only 124 incident HF events. This corresponds 
to ≈5 events per variable. Given the low ratio of events to can-
didate variables, there is reason to expect some bias in the 
estimated hazard ratios and a possibility of overfitting. To 
address this, we do not emphasize the interpretation of mar-
ginally significant variables, and we have evaluated discrimi-
nation using optimism-corrected C-indices. We acknowledge 
that replication of our findings in another similar cohort or 
external validation of our predictive model may be required to 
ensure generalizability. Finally, the patient population consists 
of clinical trial participants and may not be representative of 
the general population. Patients in either randomization arm 
were treated aggressively in terms of their CV risk factors, 
and all patients were required to complete a structured life-
style modification program. Results from the primary analysis 
of the NAVIGATOR study indicated that there was signifi-
cant reduction in BP and body weight throughout the trial.12 
Despite these limitations, this study comprised a large popula-
tion with clearly defined IGT. In these patients who were at 
risk of other adverse CV outcomes, we were able to identify 
independent and novel risk factors for HF.
Conclusions
In summary, among research participants with IGT and CV 
risk factors, we identified established and novel independent 
predictors of incident HF hospitalization. In particular, our 
findings show the importance of central adiposity and even 
normal levels of UACR as predictors of incidence HF. These 
easily identifiable risk factors will allow primary care provid-
ers to further risk stratify patients with IGT, thereby identi-
fying those who may benefit from risk factor modification, 
and potentially detecting HF earlier. These findings will also 
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allow researchers to identify patients who are most at risk and 
pursue them for future research to understand the mechanisms 
involved in the progression of IGT and insulin resistance 
to incident HF, to develop novel therapeutics and treatment 
strategies.
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Impaired glucose tolerance (IGT) is an important facet of metabolic syndrome, and is associated with increased risk of car-
diovascular disease, including heart failure (HF). Although current evidence does not support routine oral glucose tolerance 
testing to diagnose IGT, targeted screening should be considered in patients presenting with the phenotype suggestive of IGT 
and cardiometabolic risk. The aim of this study was to identify independent predictors of incident HF hospitalization among 
research participants with IGT and cardiovascular risk factors or disease (excluding HF). IGT was diagnosed using oral 
glucose tolerance test. We identified several independent predictors of incident HF hospitalization that will help clinicians 
to further risk stratify patients with IGT. These include known predictors, such as history of coronary heart disease, atrial 
fibrillation, chronic obstructive pulmonary disease, and older age. We also identified more novel markers, such as greater 
waist circumference and higher urine albumin-to-creatinine ratio. Most of these factors are readily available to clinicians 
during routine assessment. Given the adverse prognosis associated with HF, early diagnosis and possible prevention are 
important among patients at risk. Furthermore, as HF shares many common risk factors with other cardiovascular outcomes 
and chronic kidney disease, these predictors will also help clinicians identify individuals who may obtain multiple benefits 
from intensive lifestyle modification and risk factor management.
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Supplemental Material 
  
 APPENDIX 1. Endpoint definition for congestive heart failure requiring hospitalization 
Development of signs and symptoms of CHF not present at screening and requiring hospital management, or 
previously documented CHF that worsens requiring hospital management. 
CHF is clinically manifested by 1 or more of the following: 
 Dyspnea on exertion in the absence of new pulmonary disease 
 Paroxysmal nocturnal dyspnea (shortness of breath that awakens the patient from sleep) 
 Orthopnea 
AND 1 or more of the following criteria: 
 Pulmonary rales >1/3 of the way up the lung fields present after coughing in the absence of chronic lung 
disease or respiratory infection 
 Pulmonary edema on chest X-ray in absence of high suspicion for non-cardiac origin 
 New use of oral/IV diuretics, IV inotropes, IV vasodilators, or adjustment of previous diuretic dose 
 Oxygen desaturation (<90%) with no evidence of acute or chronic lung disease 
 Jugular venous distention 
 Bilateral pedal edema 
 Cardiomegaly (cardiothoracic ratio ≥0.55) 
 Left ventricular ejection fraction ≤0.40 (new or presumably new) 
 Left ventricular fractional shortening <0.25 
 S3 gallop on auscultation 
 Elevated BNP level 
BNP indicates brain natriuretic peptide; CHF, congestive heart failure; IV, intravenous. 
  
 APPENDIX 2. Candidate variables included in the all HF hospitalization model 
Demographics 
Age, y 
Female sex 
Race 
Region (Europe, North America, Latin America, 
Asia, Other) 
Anthropometric variables 
Weight, kg 
Height, cm 
BMI, kg/m2 
Waist circumference, cm 
Clinical features 
Systolic blood pressure, mm Hg  
Diastolic blood pressure, mm Hg  
Heart rate, bpm 
Medical history 
Congestive HF 
Hypertension 
Left ventricular hypertrophy 
Coronary heart disease 
Current smoker 
Atrial fibrillation or flutter 
Cerebrovascular disease 
Peripheral vascular disease 
Medical history (continued) 
Renal dysfunction 
COPD/chronic bronchitis/emphysema 
Pulmonary embolism and/or DVT 
Family history of premature CHD 
Family history of diabetes 
Glycemic status 
Baseline fasting glucose level, mmol/L 
2-hour after glucose challenge, mmol/L 
Glycated hemoglobin (HbA1c), % 
Baseline ECG interpretation 
Clinically insignificant abnormality (vs. normal) 
Clinically significant abnormality (vs. normal) 
Baseline laboratory results 
Sodium, mmol/L 
Potassium, mmol/L 
Hemoglobin, g/L 
Platelets, x109/L 
White blood cells, x109/L 
eGFR, mL/min/1.73m2 
Log urinary albumin:creatinine ratio 
HDL cholesterol, mmol/L 
LDL cholesterol, mmol/L 
Triglycerides, mmol/L 
BMI indicates body mass index; COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease; DVT, deep vein 
thrombosis; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HF, heart 
failure; LDL, low-density lipoprotein 
  
 APPENDIX 3. Multivariable Cox proportional hazards model showing independent baseline 
predictors of all heart failure hospitalizations among patients with impaired glucose tolerance 
Baseline Characteristics HR (95% CI) χ2 Statistics P value 
History of congestive HF 4.41 (3.10–6.26) 68.61 <0.001 
History of atrial fibrillation or flutter 2.98 (2.05–4.33) 32.51 <0.001 
History of coronary heart disease 2.23 (1.60–3.11) 22.64 <0.001 
Waist circumference (per 10 cm increase) 1.28 (1.16–1.42) 22.37 <0.001 
Baseline clinically significant abnormal ECG (vs. normal) 2.73 (1.77–4.22) 20.46 <0.001 
Age (per 10 year increase) 1.62 (1.31–2.00) 19.96 <0.001 
History of COPD/emphysema/chronic bronchitis 2.11 (1.43–3.13) 13.89 <0.001 
Systolic BP up to 130 mm Hg* (per unit increase) 0.97 (0.95–0.99) 13.21 <0.001 
Hemoglobin (per 10g/L decrease) 1.23 (1.10–1.38) 12.32 <0.001 
Log of urinary albumin:creatinine ratio 1.17 (1.05–1.30) 8.71 0.003 
Platelets (per 10 unit increase) 0.97 (0.94–0.99) 6.99 0.008 
eGFR (per 10 unit decrease) 1.11 (1.02–1.21) 6.24 0.013 
Height (per 10 cm increase) 0.81 (0.69–0.96) 5.85 0.016 
History of PAD 1.82 (1.09–3.06) 5.17 0.023 
Baseline clinically insignificant abnormal ECG (vs. normal) 1.62 (1.06–2.46) 5.00 0.025 
White blood cells (per 10 unit increase) 1.10 (1.01–1.20) 4.43 0.035 
Continuous variables are presented as mean ± standard deviation (SD). Categorical variables are presented as actual frequency 
(n) and percentage (%). 
Overall C-statistic for this model was 0.864.  
*Selected due to nonlinearity of systolic blood pressure as a continuous variable. 
BP indicates blood pressure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; ECG, electrocardiograph; 
eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; PAD, peripheral artery disease. 
 
 
